Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry [2]. Core Insights - During the period from March 9 to March 15, 2026, a total of 98 innovative drugs/improved new drugs were submitted for clinical trials or market approval, with 82 domestic and 16 imported applications [8]. - A total of 86 innovative drugs/improved new drugs received "implied permission" for clinical trials, including 48 chemical drugs and 37 biological drugs [8]. - Notable drugs include SG-12 injection for chronic hepatitis B and SKB-575 injection for atopic dermatitis, both of which received clinical trial approval [9][10]. Summary by Sections 1. Domestic Innovative Drugs/Improved New Drugs - 1.1 Overview: 98 applications for clinical trials or market approval were recorded, with 82 domestic and 16 imported [8]. - 1.2 Clinical Trial Approvals: 86 drugs received implied permission for clinical trials, including significant drugs like SG-12 and SKB-575 [8][9]. - 1.3 Market Approvals: No new drugs were approved for market this week [29]. 2. Domestic Generic Drugs/Biosimilars - 2.1 Overview: 41 applications for generic drugs were submitted, with 36 for new registration and 4 for clinical trials [30]. - 2.2 Consistency Evaluation: 6 products passed consistency evaluation, with a total of 55 products deemed equivalent [31]. 3. Policy and Regulation - 3.1 Policy Overview: The report summarizes key policies affecting the pharmaceutical industry, including the implementation of the Drug Administration Law [3]. - 3.2 Detailed Policy Explanation: Specific regulations and their implications for the industry are discussed [3]. 4. Global Innovative Drug Development - 4.1 Global R&D Overview: The report highlights the progress of the top 10 innovative drugs globally, including significant approvals and clinical trial results [4]. - 4.2 Clinical Trial Outcomes: The report details both successful and failed clinical trials for various drugs, indicating the competitive landscape [4].

Macro and Strategy Research - The US non-farm employment data for February was significantly below market expectations, continuing the slowdown trend since the end of 2025. The labor participation rate has slightly decreased after adjustments, and while the unemployment rate has increased, it remains within a controllable range. Inflation data appears stable, aligning with market expectations, but core goods are outperforming core services, indicating tariff transmission effects in sectors like apparel [2][3] - In Europe, the reliance on oil imports is higher, making the situation more challenging, with markets pricing in a potential interest rate hike by the European Central Bank this year [3] Fixed Income Research - February CPI showed an increase in both year-on-year and month-on-month growth, driven by seasonal factors and rising international oil prices, which also impacted PPI. The core inflation is expected to seasonally decline in March, with input factors remaining significant [6] - The central bank net injected 500 billion yuan into the market, with funding prices slightly rising. The issuance of bonds in the primary market decreased, with a total of 63 bonds issued, amounting to 414.2 billion yuan [6][8] - The long-term interest rates are under pressure due to rising inflation expectations, particularly from the increase in international oil prices. The market is advised to cautiously observe inflation changes in the short term [7][8] Industry Research - Eli Lilly has invested $3 billion to enhance its supply chain in China, indicating strong interest in the Chinese pharmaceutical market [9] - Several pharmaceutical companies have been added to the Hong Kong Stock Connect list, reflecting growing investor interest [10] - The SW pharmaceutical sector index rose by 2.49% during the week, with all sub-sectors showing gains. The overall industry P/E ratio is 49.25 times, with a valuation premium of 245% compared to the CSI 300 [10] - The report maintains a "neutral" rating for the industry, with specific buy and hold recommendations for companies like Heng Rui Medicine and WuXi AppTec, while also highlighting the potential impact of rising raw material prices on pharmaceutical companies [11]

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Changchun Tianqing Pharmaceutical, has received clinical trial approval from the National Medical Products Administration for its innovative drug TQB3205, aimed at treating advanced malignant tumors [1] Group 1: Drug Development - TQB3205 is an oral pan-KRAS inhibitor that effectively suppresses the proliferation of various KRAS-mutant tumor cells [1] - The company plans to accelerate the clinical development of TQB3205 to overcome existing treatment limitations [1] - The goal is to provide new treatment options for a broader range of patients with advanced malignant tumors harboring KRAS mutations [1]